Related Experiment Video

Updated: Mar 29, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy

Maciej Tarnowski1, Agnieszka Paradowska-Gorycka2, Ewa Dąbrowska-Zamojcin3

  • 1a Department of Physiology , Pomeranian Medical University , 70-111 Szczecin , Poland.

Expert Opinion on Drug Metabolism & Toxicology
|November 27, 2015
PubMed
Abstract

Insights

Genetic factors may influence rheumatoid arthritis (RA) treatment response, but current evidence is inconclusive for personalized medicine. Further research is needed to reliably predict drug efficacy and toxicity in RA patients.

Area of Science:

  • Pharmacogenetics
  • Rheumatology
  • Genomics

Background:

  • Rheumatoid arthritis (RA) is a systemic autoimmune disease causing joint destruction.
  • Current RA treatment relies on disease-modifying anti-rheumatic drugs (DMARDs) and biologics.
  • Patient response to RA therapies varies significantly.

Purpose of the Study:

  • To review the role of genetic polymorphisms in predicting RA treatment outcomes.
  • To explore genetic predictors for efficacy and toxicity of DMARDs and biologics in RA.

Main Methods:

  • Literature review of studies on genetic polymorphisms and RA therapy.
  • Analysis of predictors for methotrexate, leflunomide, sulfasalazine, anti-TNF-alpha, Tocilizumab, and Rituximab response.

Main Results:

  • Studies suggest associations between genetic polymorphisms and RA treatment response.
  • However, findings are largely inconclusive and inconsistent across studies.
  • Predictive value of genetic markers for RA drug efficacy and toxicity remains uncertain.

Conclusions:

  • Current pharmacogenetic data is insufficient for routine clinical application in RA.
  • Inconsistencies stem from small sample sizes, varied outcome definitions, and limited SNP analysis.
  • Epigenetic factors are under-explored and may impact personalized RA therapy.
Keywords:
polymorphismrheumatoid arthritistherapy

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
112
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
168
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76